PaxMedica, Inc. (PXMD)
US Market

PaxMedica, Inc. (PXMD) Stock Price & Analysis


PXMD Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.26 - $10.48
Previous Close$1.36
Average Volume (3M)1.08M
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$3.99M
Total Debt (Recent Filing)$1.54M
Price to Earnings (P/E)-0.8
May 15, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding14,619,477
10 Day Avg. Volume148,327
30 Day Avg. Volume1,083,101
Standard Deviation0.19
Financial Highlights & Ratios
Price to Book (P/B)180.06
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was PaxMedica, Inc.’s price range in the past 12 months?
PaxMedica, Inc. lowest stock price was $1.26 and its highest was $10.48 in the past 12 months.
    What is PaxMedica, Inc.’s market cap?
    Currently, no data Available
    When is PaxMedica, Inc.’s upcoming earnings report date?
    PaxMedica, Inc.’s upcoming earnings report date is May 15, 2023 which is 21 days ago.
      How were PaxMedica, Inc.’s earnings last quarter?
      PaxMedica, Inc. released its earnings results on Mar 29, 2023. The company reported -$0.434 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.434.
        Is PaxMedica, Inc. overvalued?
        According to Wall Street analysts PaxMedica, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does PaxMedica, Inc. pay dividends?
          PaxMedica, Inc. does not currently pay dividends.
          What is PaxMedica, Inc.’s EPS estimate?
          PaxMedica, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does PaxMedica, Inc. have?
          PaxMedica, Inc. has 14,619,477 shares outstanding.
            What happened to PaxMedica, Inc.’s price movement after its last earnings report?
            PaxMedica, Inc. reported an EPS of -$0.434 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.471%.
              Which hedge fund is a major shareholder of PaxMedica, Inc.?
              Currently, no hedge funds are holding shares in PXMD


              PaxMedica, Inc. Stock Smart Score

              Not Ranked


              Return on Equity
              Trailing 12-Months
              Asset Growth
              Trailing 12-Months
              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description

              PaxMedica, Inc.

              PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.


              Top 5 ETFs holding PXMD

              Currently, no data available
              Please return soon. This page is being updated.
              Up to five ETFs with an Outperform Smart Score that hold PXMD. The ETFs are listed according to market value of PXMD within the ETF


              Forecast EPS vs Actual EPS

              Similar Stocks
              Price & Change
              Satsuma Pharmaceuticals
              Lowell Farms
              Zynerba Pharmaceuticals
              Real Brands
              Angion Biomedica

              Popular Stocks

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis